Seattle Genetics Drug Scratches Out Win In Hodgkin Lymphoma

In a closely watched result, Adcentris, a cancer drug sold by the biotech firm Seattle Genetics and the Japanese drug giant Takeda, outperformed traditional chemotherapy in front-line Hodgkin lymphoma, a result that is likely to lead to a broadened approval from the Food and Drug Administration.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NASDAQ:SGEN Source Type: news